The companies submitted Phase III clinical trial data to FDA as a supplemental application for their vaccine, which is already approved for adults and children as young as 16.
Related posts:
Recall or science? Newsom’s sudden reopening push has many wondering
Biden administration frets J&J may miss vaccine goal
Pfizer seeks full FDA approval of its Covid-19 vaccine
Covid response chief has no regrets on Johnson & Johnson pause
Pandemic Olympics come to an end in Tokyo
Pentagon will seek to mandate Covid vaccine for 1.4 million troops
GOP, industry signal fight over potential Biden vaccine ‘threat’
DeSantis faces new resistance over mask rules
NIH director sees ‘no signs’ of a Delta peak
Departing FDA regulators pan Covid boosters in paper
Fauci: Booster shots for Americans won’t deprive unvaccinated people around the globe
Chinese city Xi’an lifts some restrictions after lockdown
